HPV mRNA LNP vaccine
By designing the new 5'UTR sequence and optimizing the composition of lipid nanoparticles, the translation efficiency and stability of HPV mRNA LNP vaccines are improved, and the problems of low translation efficiency and poor stability of mRNA vaccines in the prior art are solved, achieving efficient Immune reactions and low toxic side effects.
Patent Information
- Application Number
- CN202310528807.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-11
- Publication Date
- 2024-11-12
AI Technical Summary
Among existing mRNA vaccines and gene therapies, mRNA translation efficiency and stability are low, resulting in poor treatment effects and high cost, and there are problems with stability and distribution specificity of lipid nanoparticles during delivery.
A new 5'UTR sequence was designed to improve the translation efficiency of mRNA and to form a combination containing HPV antigen-encoded mRNA by optimizing the composition of lipid nanoparticles including ionizable cationic lipids, PEG-modified lipids, phospholipids and cholesterol. for the construction of efficient HPV mRNA LNP vaccine.
The HPV mRNA LNP vaccine was achieved with excellent immunogenicity, local high expression, low liver targeting and excellent stability, which significantly improved the therapeutic effect and reduced costs.
Smart Images

Figure CN118924887A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of HPV mRNA LNP vaccines. Background Art
[0002] mRNA vaccines, mRNA therapies and gene therapies are intended to treat or prevent various diseases using mRNA and genes encoding disease-specific proteins. In current mRNA vaccines and mRNA therapies, mRNA is produced by in vitro transcription of genes encoding target proteins and is administered to patients. The mRNA is then translated into target proteins in vivo, which triggers the host's immune response to, for example, cancer cells and / or viruses, thereby leading to the eradication of tumors and / or viruses, and / or preventing tumor recurrence and / or viral infection / reinfection. On the other hand, gene therapy introduces target genes into patients. These target genes are transcribed and translated in vivo to produce target proteins. Therefore, improving the transcription and translation efficiency of genes encoding target proteins is a key factor in improving the therapeutic effects of mRNA vaccines, mRNA therapies and gene therapies, as well as reducing the costs of mRNA vaccines and mRNA therapies.
[0003] 5'UTR is a sequence upstream of the mRNA coding region and is a central regulator of mRNA translation into protein. Ribosomes recognize 5'UTR and initiate translation of mRNA. Each mRNA has a unique 5'UTR sequence to control the translation of mRNA. It has been shown that the translation efficiency of mRNA depends largely on the thermodynamic stability, position and GC content of the RNA structure in the 5'UTR (Babendure JR et al. RNA. 2006.12:851). However, the optimal 5'UTR structure has not yet been determined. In response to this, we designed a new and optimal 5'UTR sequence for the translation of HPV antigen-encoding mRNA.
[0004] As a new delivery carrier for nucleic acid therapeutic drugs, lipid nanoparticles (LNP) have, to a certain extent, solved the technical problems of poor in vitro and in vivo stability of nucleic acid therapeutic drugs, difficulty in endosome escape, and lack of specificity in tissue distribution. On this basis, by optimizing the selected lipid nanoparticle (LNP) prescription ratio and the selection of protonable cationic lipids, the efficient encapsulation of nucleic acid drugs and the provision of sufficient external protection to prevent their degradation are achieved, and the endosome escape is promoted to achieve efficient delivery of nucleic acid drugs in vivo. Therefore, we constructed an HPV antigen encoding mRNA sequence containing a new 5'UTR sequence, and prepared an HPV mRNA LNP vaccine containing the mRNA sequence. The results show that the HPV mRNA LNP of the present invention exhibits excellent in vivo immunogenicity, local high expression, lower liver targeting, and excellent stability. BRIEF DESCRIPTION OF THE DRAWINGS
[0005] Figure 1 Modulation of the translation efficiency of the FLuc gene by 5'UTR sequence optimization is shown.
[0006] Figure 2 Shown are the results of a comparison of the transcription efficiencies of FLuc genes containing various 5'UTR sequences.
[0007] Figure 3 Comparative results of translation efficiency of HPV mRNAs containing various 5'UTR sequences are shown.
[0008] Figure 4A , 4B , 4C shows the comparison of translation efficiency of HPV mRNA containing various 5'UTR sequences.
[0009] Figure 5 Comparison of in vivo fluorescence expression of muscles of lipid nanoparticles prepared with various cationic phospholipids at different ratios
[0010] Figure 6 The results show the comparison of in vivo fluorescence expression of organs in lipid nanoparticles prepared with various cationic phospholipids at different ratios.
[0011] Figure 7 The results show the in vivo immunogenicity comparison of lipid nanoparticles prepared with various cationic phospholipids at different ratios. DETAILED DESCRIPTION OF THE INVENTION
[0013] In one embodiment, the present invention provides a composition comprising lipid nanoparticles (LNP) and mRNA, wherein:
[0014] The mRNA comprises in the 5' to 3' direction:
[0015] at least one 5'UTR element, the 5'UTR element being SEQ ID NO. 38, and
[0016] Open reading frame (ORF) encoding HPV antigen sequence;
[0017] The LNPs contain ionizable cationic lipids, PEG-modified lipids, phospholipids and cholesterol.
[0018] In one aspect, the HPV antigen sequence in the composition of the present invention comprises the sequence shown in SEQ ID NO:56.
[0019] In one aspect, the mRNA in the composition of the present invention further comprises a 3'UTR element and a polyA sequence as shown in SEQ ID NO:55.
[0020] In one aspect, the composition of the present invention comprises 20-60 mol% ionizable cationic lipid, 0.5-15 mol% PEG-modified lipid, 5-25 mol% phospholipid and 25-55 mol% cholesterol.
[0021] In one aspect, the cationic lipid in the composition of the present invention is SM-102.
[0022]
[0023] (SM-102)
[0024] In one aspect, in the composition of the present invention, the LNP comprises 46.3 mol% SM-102, 1.6 mol% PEG-modified lipids, 9.4 mol% phospholipids and 42.7 mol% cholesterol.
[0025] In one aspect, the PEG-modified lipid in the LNP is PEG2000-DMG, and the phospholipid is DSPC.
[0026] On the one hand, in the composition of the present invention, the mRNA is the sequence shown in SEQ ID NO:57.
[0027] In one aspect, in the composition of the invention, the mRNA comprises at least one modified or non-naturally occurring nucleotide.
[0028] In one aspect, in the compositions of the invention, the at least one modified or non-naturally occurring nucleotide comprises at least one backbone modification, sugar modification or base modification.
[0029] In one aspect, in the composition of the present invention, the at least one modified or non-naturally occurring nucleotide comprises at least one base modification, wherein the base modification is selected from the group consisting of 2-amino-6-chloropurine-nucleoside-5'-triphosphate, 2-aminoadenosine-5'-triphosphate, 2-thiocytidine-5'-triphosphate, 2-thiouridine-5'-triphosphate, 4-thiouridine-5'-triphosphate, 5-aminoallylcytidine-5'-triphosphate, 5-aminoallyluridine-5'-triphosphate, 5-bromocytidine-5'-triphosphate, 5-bromouridine-5'-triphosphate, 5-iodine-5'-triphosphate, 5-iodouridine-5'-triphosphate, 5-methylcyt ... Uridine-5'-triphosphate, 6-azacytidine-5'-triphosphate, 6-azauridine-5'-triphosphate, 6-chloropurine-nucleoside-5'-triphosphate, 7-deazaadenosine-5'-triphosphate, 7-deazaguanosine-5'-triphosphate, 8-azaadenosine-5'-triphosphate, 8-azidoadenosine-5'-triphosphate, benzimidazole-nucleoside-5'-triphosphate, N1-methyladenosine-5'-triphosphate, N1-methylguanosine-5'-triphosphate, N6-methyladenosine-5'-triphosphate, O6-methylguanosine-5'-triphosphate, N1-methyl-methyluracil-5'-triphosphate, puromycin-5'-triphosphate, xanthine-5'-triphosphate, methyluracil-5'-triphosphate.
[0030] In one embodiment, the present invention provides a pharmaceutical composition comprising a composition of the present invention and one or more pharmaceutically acceptable excipients.
[0031] In one embodiment, the present invention provides use of the composition of the present invention in the preparation of a medicament for treating or preventing a disease, wherein the disease is selected from HPV infection or a disease or condition caused by HPV infection.
[0032] On the one hand, the disease or condition caused by HPV infection in the present invention is HPV-related cancer. DETAILED DESCRIPTION
[0033] Example 1. Characterization of 5'UTR sequence
[0034] The novel 5'UTR sequences generated and tested in this study are listed below in Table 1. All of these sequences were designed in-house to achieve high MRL scores predicted using the Optimus 5-Prime program.
[0035] Table 1 5'UTR sequence of the present invention
[0036]
[0037]
[0038]
[0039]
[0040] *5'UTR 001 (SEQ ID NO. 52) is SEQ ID NO. 20 disclosed in WO2013071047A1.
[0041] The secondary structures of the 5'UTR sequences tested in this study were predicted using the RNA Folding Form V2.3 program (http: / / www.unafold.org / mfold / applications / rna-folding-form-v2.php). The secondary structures of the 5'UTR sequences of the invention tested in this study had the largest negative delta G.
[0042] Example 2. Regulation of the translation efficiency of the FLuc gene by 5'UTR sequence optimization
[0043] The firefly luciferase gene (FLuc) is widely used as a reporter gene to study UTR-regulated transcription and translation. The FLuc gene with various 5'UTR sequences was cloned using a T7 expression plasmid vector (NCBI GeneBank: MK484107.1), where the FLuc gene was expressed under the control of the T7 promoter. Capped FLuc mRNA was generated using HiScribe TM T7 High Yield RNA Synthesis Kit (NEB, Ipswich, MA) and CleanCap AG (Trilink, San Diego, CA) were used to generate in vitro transcription. To measure the efficiency of FLuc mRNA translation, 500 ng of FLuc mRNA was transfected in HeLa cells (ATCC, Manassas, VA) using Lipofectamine MessengerMAX (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's instructions. After 24 hours of incubation, the level of FLuc protein was indirectly determined by measuring luciferase activity using the Bio-Lite Luciferase Assay System (Vazyme, Nanjing, China). The relative luciferase activity was normalized to the FLuc mRNA containing the 5'UTR sequence of Moderna's COVID vaccine mRNA-1273.
[0044] like Figure 1As shown, the FLuc mRNA containing the novel 5'UTR sequence (sequence name: 2, 001-opt, 17-opt, 18-opt or HBB-opt) produced 1.5 to 2.7 times more FLuc protein than the FLuc mRNA containing the 5'UTR sequence of mRNA-1273. However, the FLuc mRNA containing the novel 5'UTR sequence (sequence name: 8, 17, 18 and 24) produced 0.5 to 0.6 times less FLuc protein than the FLuc mRNA containing the 5'UTR sequence of mRNA-1273.
[0045] Interestingly, the MRL score did not directly correlate with the efficiency of Fluc mRNA translation. In addition, there was no significant relationship between mRNA secondary structure and translation efficiency.
[0046] Example 3. Comparison of FLuc gene transcription efficiency with different 5'UTR sequences
[0047] To determine the effect of 5'UTR sequence on FLuc gene transcription efficiency, HiScribe TM T7 High Yield RNA Synthesis Kit (NEB) was used to transfect 0.5 μg of expression plasmid in vitro, which contained a Fluc gene with various 5'UTRs under the control of a T7 promoter. After 2 hours of in vitro transcription, the plasmid template was digested with DNase I, and then the mRNA was purified using magnetic beads (Yeasen, Shanghai, China). The amount of mRNA was measured using a NanoDrop spectrophotometer (Thermo Fisher Scientific). The amount of Fluc mRNA transcripts was standardized to the amount of Fluc mRNA transcripts expressed by the Fluc gene containing the 5'UTR sequence of Moderna's COVID vaccine mRNA-1273.
[0048] like Figure 2 As shown, the Fluc mRNA transcripts produced by the Fluc genes containing the following 5'UTR sequences are comparable to the Fluc mRNA transcripts produced by the Fluc gene containing the 5'UTR sequence of mRNA-1273: 1, 4, 5, 6, 9, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 001-30+HBB, 001, 001-opt, 17-opt, 18-opt, HBB-opt, HBB long, miniUTR3+, miniUTR3, miniUTR7+, miniUTR7, or RPL32.
[0049] Interestingly, the FLuc genes containing the novel 5'UTR sequences 2, 3, 7, 8, 11, 25, HBA1 mut, and HBB short produced 0.2 to 0.7-fold less FLuc mRNA transcripts than the FLuc genes containing the 5'UTR sequence of mRNA-1273.
[0050] Example 4. Comparison of translation efficiency of HPVs containing various 5'UTR sequences
[0051] The HPV antigen polypeptide coding sequence with various 5'UTR sequences as described in Table 1 was cloned using T7 expression plasmid vectors. Capped HPV mRNA was produced by in vitro transcription using T7 polymerase (Roche) and Clean Cap AG (Trilink). Among them, the HPV antigen polypeptide coding sequence is SEQ ID NO: 56. The mRNA sequence containing HBB-opt 5'UTR (SEQ ID NO: 38) and the HPV antigen polypeptide coding sequence is SEQ ID NO: 57.
[0052] To measure the HPV mRNA translation efficiency, 500 ng of HPV mRNA was transfected into 293Hek cells using lipofectamine MessengerMAX according to the manufacturer's instructions. Figure 3 ) or incubate for 24 hours ( Figure 4A ) / 48 hours( Figure 4B ) / 72 hours( Figure 4C ) were used to measure HPV protein levels using flow cytometry and anti-E7-PE conjugated antibodies (Santa Cruz Biotechnology). Flow cytometry analysis was performed on an Attune NxT Focusing Cytometer (ThermoFisher Scientific). Data analysis was performed using FlowJo software (BD Life Sciences). To quantify the results, Prism 4 (GraphPad Software, Inc.) was used to plot the percentage of positive cells.
[0053] like Figure 3 As shown, BNT162b2 is the preferred 5'UTR of BioNtech for its commercial COVID-19 vaccine. Among the screened 5'UTRs, hHBB 5UTR-kozak (SEQ ID NO: 36) significantly improved the translation efficiency of the HPV antigen polypeptide coding sequence compared to BioNtech's 5'UTR (BNT162b2).
[0054] As shown in Figure 4, as expected, protein expression decreased over time in all groups. At 72 hours post-transfection, our HPV mRNA with HBB-opt 5'UTR (SEQ ID NO: 38) showed increased E7 protein expression compared to the baseline 5'UTR. No significant differences in E7 protein expression were observed at 24 hours and 48 hours post-translation.
[0055] Example 5. Preparation of mRNA LNP
[0056] A certain amount of cationic lipids (SM-102, MC3, HUO-1 (Sinobond), B-0315 (Sinobond)), DSPC, cholesterol, PEG2000-DMG were weighed and prepared into a 40mM phospholipid ethanol solution at the required molar ratio. The mRNA was diluted with an acetate buffer at pH = 4.0, and the mass ratio of phospholipid to mRNA was 20:1. The above phospholipid ethanol solution and the mRNA aqueous solution were mixed on a microfluidic device (Inano system) at a volume ratio of 1:3, and the final mRNA LNP preparation was obtained after ultrafiltration and dialysis.
[0057] Table 2 LNP formulation composition information
[0058]
[0059]
[0060] Example 6. In vivo fluorescence transfection experiment of mRNA LNP lipid nanoparticles
[0061] Animal transfection experiment of mRNA LNP lipid nanoparticles Balb / c mice (animal source: Jiangwei Tonglihua Experimental Animal Technology Co., Ltd., male, 6-8 weeks old, 20-24g) were randomly divided into groups, with 5 mice in each group. The prepared lipid nanoparticles were injected into the leg muscles at a dose of 0.1 mg / kg, and in vivo imaging observation was performed 24 hours later. The injection sites of the abdomen and legs of Balb / c mice were prepared, and after the animals were anesthetized, D-luciferin potassium salt was injected intraperitoneally. The animals were observed and images were taken using an IVIS in vivo imager (PerkinElmer, Series Ⅲ). The in vivo imaging observation time was within 15 minutes after the injection of the substrate. The results of local muscle expression are shown in the figure. Figure 5 shown.
[0062] The results showed that the local expression of SM-102LNP in animals was 2-5 times better than that of LNP prepared from other ionizable cationic materials. Moreover, at a ratio of SM-102 to ionizable cationic phospholipids of 46.3, the local protein expression in mice was 1.5-2 times higher than that of other similar SM-102LNP formulations. Its local expression ability is one of the focuses of vaccine products.
[0063] Example 7. In vivo fluorescence transfection experiment of mRNA LNP lipid nanoparticles
[0064] Animal transfection experiment of mRNA LNP lipid nanoparticles Balb / c mice (animal source: Jiangwei Tonglihua Experimental Animal Technology Co., Ltd., male, 6-8 weeks old, 20-24g) were randomly divided into groups, with 5 mice in each group. The prepared lipid nanoparticles were injected into the leg muscles at a dose of 0.1 mg / kg, and in vivo imaging observation was performed 24 hours later. The injection sites of the abdomen and legs of Balb / c mice were prepared, and after the animals were anesthetized, D-luciferin potassium salt was injected intraperitoneally. The animals were observed and images were taken using an IVIS in vivo imager (PerkinElmer, Series Ⅲ). The in vivo imaging observation time was within 15 minutes after the injection of the substrate. The results are as follows Figure 6 shown.
[0065] The results showed that the amount of SM-102 46.3 ratio LNP in the organs of animals was 1.5-3 times lower than that of other similar ratio SM-102 LNPs, reflecting the local expression characteristics of SM-102 46.3 ratio LNP, which does not enter the blood and accumulate in organs, greatly reducing toxic side effects and improving the safety of this mRNA LNP.
[0066] Example 8. In vivo immunogenicity experiment of mRNA LNP lipid nanoparticles
[0067] In the experiment, C57BL / 6 mice (animal source: Jiangwei Tonglihua Experimental Animal Technology Co., Ltd., female, 6-8 weeks old, a total of 25) were randomly divided into groups, with 5 mice in each group. The prepared HPV mRNA LNP lipid nanoparticles were injected into the leg muscle at a dose of 0.4 mg / kg, and were administered 3 times on D1, D7, and D14, respectively. The spleen was taken on D21 and stored in RPMI-1640+double-antibody culture medium for subsequent experiments.
[0068] Grind and filter the mouse spleen, collect it in a 15ml centrifuge tube, and centrifuge it at 400g for 5min. Discard the supernatant, add red blood cell lysis buffer, mix well, incubate at room temperature for 3min, add cell culture medium to terminate lysis, and centrifuge it at 400g for 5min. Discard the supernatant and wash it once with DPBS. Discard the supernatant, add cell culture medium, mix well, and count the cells. Set the cell density for plating to 1x105 cells / well. When plating, first add the prepared HPV 16E6 Peptide / HPV 16E7 Peptide / PMA stimulator (peptide from GenScript Biotech Co., Ltd., PMA from Dakoway Biotech Co., Ltd.), and then add the corresponding cell suspension. Place the plate in a 37℃ 5% CO2 incubator and incubate overnight (full 12 hours). Take out for ELISpot detection: take out the plate, wash it with DPBS 5 times, pat dry after the last wash, add the prepared antibody MTAM8-Biotin solution (MTAM8-Biotin: diluent = 1:500), 100ul / well, and incubate at room temperature for 2 hours. Wash it with DPBS 5 times, pat dry after the last wash, add the prepared Streptavidin-ALP solution (Streptavidin-ALP: diluent = 1:1000), 100ul / well, and incubate at room temperature for 1 hour. Wash with DPBS 5 times, pat dry after the last wash, add BCIP / NBT-plus Substrate, color development reagent, and color for 7 minutes. Then rinse gently with tap water to stop color development. Finally, count the spots after the plate is dry and analyze the data. The results are as follows Figure 7 shown.
[0069] The results showed that when SM-102LNP was prepared at a ratio of 46.3, mice were immunized in vivo and stimulated by the E7 peptide library, compared with SM-102LNP with other ratios. In addition, SM-102 showed significant differences in immunogenicity when compared with different types of ionizable materials (MC3 LNP) at the same ratio.
[0070] Example 9. mRNA LNP stability test
[0071] Weigh a certain amount of cationic lipids (SM-102, MC3), DSPC, cholesterol, and PEG2000-DMG, and prepare a 40mM phospholipid ethanol solution at the required molar ratio. Use an acetate buffer with a pH of 4.0 to dilute mRNA, and the mass ratio of phospholipids to mRNA is 20:1. The above-mentioned phospholipid ethanol solution and the mRNA aqueous solution are mixed on a microfluidic device (Maianna, Inano system) at a volume ratio of 1:3, and the final mRNA LNP preparation is obtained by ultrafiltration and dialysis. After sampling, the remaining sample is placed at -80°C for storage for one week and then subjected to pharmacological testing.
[0072] Table 3 Pharmaceutical characterization of fresh samples after preparation of HPV mRNA LNP
[0073] Sample name Particle size PDI Potential Encapsulation rate (%) mRNA integrity Time G1(SM-102 43.3) 78.6 0.15 1.43 91.2 89.4 0 o'clock G2(SM-102 46.3) 82.7 0.11 3.53 93.1 91.1 0 o'clock G3(SM-102 48) 77.2 0.12 3.25 91.4 92.3 0 o'clock G4(SM-102 50) 75.2 0.11 3.12 92.4 92.3 0 o'clock G5 (MC3 46.3) 88.3 0.1 5.31 92.3 88.4 0 o'clock
[0074] Table 4 Preparation characteristics of HPV mRNA LNP samples after freezing at -80 degrees for one week
[0075] Sample name Particle size PDI Potential Encapsulation rate (%) mRNA integrity Storage conditions G1(SM-102 43.3) 119.7 0.23 2.42 87.5 84.6 -80 degrees, store for one week G2(SM-102 46.3) 86.9 0.14 4.31 92.8 90.4 -80 degrees, store for one week G3(SM-102 48) 84.2 0.18 5.67 88.9 90 -80 degrees, store for one week G4(SM-102 50) 85.5 0.15 1.25 90.4 90.6 -80 degrees, store for one week G5 (MC3 46.3) 98.9 0.2 4.32 86.8 84.9 -80 degrees, store for one week
[0076] The results showed that the particle size of SM-102HPV mRNA LNP increased by more than 40nm after freezing at a preparation ratio of 43.3, and the preparation was unstable during freezing. However, SM-102HPV mRNA LNP above 46.3 showed better particle size, distribution and mRNA integrity after freezing, but the encapsulation rate of LNPs with a ratio of 48 and 50 decreased slightly more than that of SM-102LNP with a ratio of 46.3, indicating that the stability of mRNA inside LNP was better than that of SM-102LNP with a ratio of 46.3. MC3 mRNA LNP was not as good as SM-102mRNA LNP in terms of overall formulation characteristics.
Claims
1. A composition comprising lipid nanoparticles (LNP) and mRNA, wherein (1) The mRNA comprises, in the 5' to 3' direction: a) at least one 5'UTR element, the 5'UTR element being SEQ ID NO. 38, and b) an open reading frame (ORF) encoding an HPV antigen sequence; (2) The LNP comprises ionizable cationic lipids, PEG-modified lipids, phospholipids and cholesterol.
2. The composition of claim 1, wherein the HPV antigen sequence comprises the sequence shown in SEQ ID NO:
56.
3. The composition of claim 1, wherein the mRNA further comprises a 3'UTR element and a polyA sequence as shown in SEQ ID NO:
55.
4. The composition of claim 1, wherein the LNP comprises 20-60 mol% ionizable cationic lipids, 0.5-15 mol% PEG-modified lipids, 5-25 mol% phospholipids, and 25-55 mol% cholesterol.
5. The composition of claim 1, wherein the cationic lipid is SM-102.
6. The composition of claim 1, wherein the LNP comprises 46.3 mol% SM-102, 1.6 mol% PEG-modified lipids (such as PEG2000-DMG), 9.4 mol% phospholipids (such as DSPC) and 42.7 mol% cholesterol.
7. The composition of claim 1, wherein the mRNA is the sequence shown in SEQ ID NO:
57.
8. The composition of claim 1, wherein the mRNA comprises at least one modified or non-naturally occurring nucleotide.
9. The composition of claim 8, wherein the at least one modified or non-naturally occurring nucleotide comprises at least one backbone modification, sugar modification, or base modification.
10. The composition of claim 8, wherein the at least one modified or non-naturally occurring nucleotide comprises at least one base modification, wherein the base modification is selected from the group consisting of 2-amino-6-chloropurine-nucleoside-5'-triphosphate, 2-aminoadenosine-5'-triphosphate, 2-thiocytidine-5'-triphosphate, 2-thiouridine-5'-triphosphate, 4-thiouridine-5'-triphosphate, 5-aminoallylcytidine-5'-triphosphate, 5-aminoallyluridine-5'-triphosphate, 5-bromocytidine-5'-triphosphate, 5-bromouridine-5'-triphosphate, 5-iodocytidine-5'-triphosphate, 5-iodouridine-5'-triphosphate, 5-methylcytidine-5'-triphosphate, 5- Methyluridine-5'-triphosphate, 6-azacytidine-5'-triphosphate, 6-azauridine-5'-triphosphate, 6-chloropurine-nucleoside-5'-triphosphate, 7-deazaadenosine-5'-triphosphate, 7-deazaguanosine-5'-triphosphate, 8-azaadenosine-5'-triphosphate, 8-azidoadenosine-5'-triphosphate, benzimidazole-nucleoside-5'-triphosphate, N1-methyladenosine-5'-triphosphate, N1-methylguanosine-5'-triphosphate, N6-methyladenosine-5'-triphosphate, O6-methylguanosine-5'-triphosphate, N1-methyl-methyluracil-5'-triphosphate, puromycin-5'-triphosphate, xanthine-5'-triphosphate, methyluracil-5'-triphosphate.
11. A pharmaceutical composition comprising the composition of claim 1 and one or more pharmaceutically acceptable excipients.
12. Use of the composition of claim 1 in the preparation of a medicament for treating or preventing a disease, wherein the disease is selected from HPV infection or a disease or illness caused by HPV infection.
13. The use according to claim 12, wherein the disease or condition caused by the HPV infection is HPV-related cancer.
